Luiz G. Tone

3900, Bandeirantes Avenue
Ribeirao Preto, SP 14049900, Brazil

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 110 publications

Therapeutic Potential of Targeting USP2 in Pediatric Group 3 and 4 Medulloblastomas: Insights from In Silico, Ex Vivo, and In Vitro Studies.

Therapeutic Potential of Targeting USP2 in Pediatric Group 3 and 4 Medulloblastomas: Insights from In Silico, Ex Vivo, and In Vitro Studies.

Journal: Cerebellum (London, England)

Published: May 18, 2026

miR-512-3p as a Potential Biomarker of Poor Outcome in Pediatric Medulloblastoma.

miR-512-3p as a Potential Biomarker of Poor Outcome in Pediatric Medulloblastoma.

Journal: Cerebellum (London, England)

Published: February 25, 2025

Impact of a serious immersive virtual reality game in managing pain during venous or catheter procedures in Pediatric Oncology.

Impact of a serious immersive virtual reality game in managing pain during venous or catheter procedures in Pediatric Oncology.

Journal: Einstein (Sao Paulo, Brazil)

Published: August 19, 2024

Identifying prognostic hub genes and key pathways in pediatric adrenocortical tumors through RNA sequencing and Co-expression analysis.

Identifying prognostic hub genes and key pathways in pediatric adrenocortical tumors through RNA sequencing and Co-expression analysis.

Journal: Molecular and cellular endocrinology

Published: July 24, 2024

Immunomodulatory role of exosome-derived content in pediatric medulloblastoma: a molecular subgroup perspective.

Immunomodulatory role of exosome-derived content in pediatric medulloblastoma: a molecular subgroup perspective.

Journal: Human cell

Published: June 19, 2024

Analysis of miR-483-3p and miR-630 expression profile in pediatric adrenocortical tumors and the effect of their modulation on adrenal tumorigenesis in vitro.

Analysis of miR-483-3p and miR-630 expression profile in pediatric adrenocortical tumors and the effect of their modulation on adrenal tumorigenesis in vitro.

Journal: Molecular and cellular endocrinology

Published: June 18, 2024

Low PRKAB2 Expression Is Associated with Poor Outcomes in Pediatric Adrenocortical Tumors, and Treatment with Rottlerin Increases the PRKAB2 Level and Inhibits Tumorigenic Aspects in the NCI-H295R Adrenocortical Cancer Cell Line.

Low PRKAB2 Expression Is Associated with Poor Outcomes in Pediatric Adrenocortical Tumors, and Treatment with Rottlerin Increases the PRKAB2 Level and Inhibits Tumorigenic Aspects in the NCI-H295R Adrenocortical Cancer Cell Line.

Journal: Cancers

Published: December 22, 2023

Musashi-1 regulates cell cycle and confers resistance to cisplatin treatment in Group 3/4 medulloblastomas cells.

Musashi-1 regulates cell cycle and confers resistance to cisplatin treatment in Group 3/4 medulloblastomas cells.

Journal: Human cell

Published: June 05, 2023

Identification of HDAC4 as a potential therapeutic target and prognostic biomarker for ZFTA-fused ependymomas.

Identification of HDAC4 as a potential therapeutic target and prognostic biomarker for ZFTA-fused ependymomas.

Journal: Cancer gene therapy

Published: December 21, 2022

Indisulam Reduces Viability and Regulates Apoptotic Gene Expression in Pediatric High-Grade Glioma Cells.

Indisulam Reduces Viability and Regulates Apoptotic Gene Expression in Pediatric High-Grade Glioma Cells.

Journal: Biomedicines

Published: October 22, 2022

A foretaste for pediatric glioblastoma therapy: targeting the NF-kB pathway with DHMEQ.

A foretaste for pediatric glioblastoma therapy: targeting the NF-kB pathway with DHMEQ.

Journal: Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery

Published: July 12, 2022

Panobinostat (LBH589) increase survival in adult xenografic model of acute lymphoblastic leukemia with t(4;11) but promotes antagonistic effects in combination with MTX and 6MP.

Panobinostat (LBH589) increase survival in adult xenografic model of acute lymphoblastic leukemia with t(4;11) but promotes antagonistic effects in combination with MTX and 6MP.

Journal: Medical oncology (Northwood, London, England)

Published: April 25, 2022

Showing 1-12 of 110

Last Updated: 09/26/2026